Extended reimbursement for gene expression profile (GEP) testing and next-generation sequencing (NGS) in Belgium

05

Aug 2022

Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) temporarily reimburses gene expression profile (GEP) testing for early-stage breast cancer detection under a specific convention that was valid from July 01, 2019, to June 30, 2022. INAMI-RIZIV announced that it will be extended until December 31, 2022. The list of reimbursable tests, reimbursement amount, and other conditions remains the same.

Molecular biology tests by next-generation sequencing (NGS) are temporarily reimbursed by INAMI-RIZIV under a specific convention that was valid from July 01, 2019, to June 30, 2022. INAMI announced that it will be extended until June 30, 2023. The reimbursement supplements per indications are specified in Annex 4, which was updated on June 30, 2022. Other conditions remain the same.

See the full details in French and Dutch here (for GEP) and here (for NGS).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

11

Aug 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in July 2022. Twenty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular and peripheral vascular, neurovascular and neuromodulation, orthopedic, endocrine, and ENT devices, as well as breast implants and medical aids. Except for this, CNEDiMTS published two positive and two negative opinions concerning transitional coverage of devices.

Read more

10

Aug 2022

In July 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (transcatheter tricuspid valve annuloplasty for tricuspid regurgitation, and transcatheter tricuspid valve leaflet repair for tricuspid regurgitation), one new Diagnostic Guidance (PLGF-based testing to help diagnose suspected preterm pre-eclampsia), and four new Medtech Innovation Briefings (ProciseDx point-of-care platform for IBD, RespiraSense for continuously monitoring respiratory rate, Lenus COPD Support Service, and cyanoacrylate glue for hernia mesh fixation). Also, five clinical guidelines were updated.

Read more

09

Aug 2022

In May-July 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers.

Read more

27

Jul 2022

The French National Authority for Health released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in June 2022. Nineteen recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services. Opinions concern cardiovascular, interventional radiology, orthopedic, neurovascular and neuromodulation, ophthalmology, as well as medical aids.

Read more

26

Jul 2022

On June 23, 2022, the National Association of Statutory Health Insurance Physicians (KBV) announced the first steps aimed to expand the utilization of surgical procedures within day case/outpatient settings (reimbursed via the German Uniform Evaluation Standard (EBM) catalog).

Read more